Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Prognostische en voorspellende waarde van luminal-like subtype bij HR+ borstkanker
apr 2025 | Borstkanker